Authors: Manafa, P, Okoye, E, Ekuma-Okereke, O, Ukibe, R, Ibe, C, Chukwuanukwu, C, Chukwuma, O, Nwene, E, Ebugosi, S, Manafa, I, Manafa, C

Source: Medical Journal of Dr. D.Y. Patil University; Jul/Aug2020, Vol. 13 Issue 4, p306-310, 5p

Subject Terms: GLYCOLIPIDS, GLYCOSYLATED hemoglobin, DIABETES, BLOOD sugar, TEACHING hospitals, UNIVERSITY hospitals, CARBOHYDRATES

Authors: I.R. Iroha, Okoye E, Osigwe Ca, Nwakaeze Ae, C.P. Ejikeugwu, I B Moses

Source: Journal of Pharmaceutical Care & Health Systems.

Subject Terms: Cefoxitin, medicine.drug, medicine, Veterinary medicine, business.industry, business, Imipenem, Cefotaxime, Amoxicillin, Antibiotic resistance, Cefotetan, Aztreonam, chemistry.chemical_compound, chemistry, Ceftazidime, polycyclic compounds

Access URL: https://explore.openaire.eu/search/publication?articleId=doi_________::d8f11faacb57e2a32f3aecc0ac7f003b

Authors: Nwankwo, O. D., Ewuim, S. C., Okoye, E. L.

Source: Bayero Journal of Pure & Applied Sciences; Jun2019, Vol. 12 Issue 1, p127-131, 5p

Subject Terms: SPIDERS, PITFALL traps, JUMPING spiders, NUMBERS of species, CLEARCUTTING, DEMOGRAPHIC surveys

Geographic Terms: NIGERIA

Authors: Minkov, D., Yamada, H., Toyosugi, N., Morita, M., Okoye, E. K., Nihira, H., Hara, M.

Source: AIP Conference Proceedings; 2007, Vol. 902 Issue 1, p117-120, 4p, 2 Diagrams, 5 Graphs

Subject Terms: LITHOGRAPHY, SYNCHROTRONS, RADIATION, PHYSICS, PHYSICAL sciences, MANUFACTURING processes, PARTICLES (Nuclear physics)

Authors: Okoye, E. L., Ezeifeka, G. O., Esimone, C. O.

Source: Australian Journal of Herbal Medicine; 2012, Vol. 24 Issue 4, p128-134, 7p

Authors: Akil L; Department of Behavioral and Environmental Health, School of Public Health, College of Health Science, Jackson State University, Jackson, MS 39217, USA., Barner YM; Department of Health Policy and Management, School of Public Health, College of Health Science, Jackson State University, Jackson, MS 39217, USA., Bisht A; Department of Behavioral and Environmental Health, School of Public Health, College of Health Science, Jackson State University, Jackson, MS 39217, USA., Okoye E; Department of Epidemiology and Biostatistics, School of Public Health, College of Health Science, Jackson State University, Jackson, MS 39217, USA., Ahmad HA; Department of Biology, College of Science, Engineering, and Technology, Jackson State University, Jackson, MS 39217, USA.

Source: International journal of environmental research and public health [Int J Environ Res Public Health] 2022 Oct 27; Vol. 19 (21). Date of Electronic Publication: 2022 Oct 27.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238455 Publication Model: Electronic Cited Medium: Internet ISSN: 1660-4601 (Electronic) Linking ISSN: 16604601 NLM ISO Abbreviation: Int J Environ Res Public Health Subsets: MEDLINE

Authors: Lin M; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Narkcham S; Department of Pathology, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand., Jones A; BioReference Laboratories, Houston, Texas., Armylagos D; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., DiPietro B; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Okafor O; BioReference Laboratories, Houston, Texas., Tracey P; BioReference Laboratories, Houston, Texas., Vercher T; BioReference Laboratories, Houston, Texas., Vasquez S; BioReference Laboratories, Houston, Texas., Haley S; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Crumley S; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Gorman B; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Jacobi E; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Amrikachi M; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Coffey D; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Mody D; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Okoye E; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas. Electronic address: EIOkoye@houstonmethodist.org.

Source: Journal of the American Society of Cytopathology [J Am Soc Cytopathol] 2022 Sep 13. Date of Electronic Publication: 2022 Sep 13.

Publication Type: Published Erratum

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101613234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2945 (Print) Linking ISSN: 22132953 NLM ISO Abbreviation: J Am Soc Cytopathol Subsets: MEDLINE

Authors: Stewart MD; Friends of Cancer Research. Electronic address: mstewart@focr.org., McCall B; Genentech, A Member of the Roche Group., Pasquini M; Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research., Yang AS; Xencor., Britten CD; Amgen., Chuk M; Food and Drug Administration., De Claro RA; Food and Drug Administration., George B; Food and Drug Administration., Gormley N; Food and Drug Administration., Horowitz MM; Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research., Kowack E; Xencor., McCoy C; Bristol Myers Squibb., Morrow PK; Amgen., Okoye E; Regeneron Pharmaceuticals., Ricafort R; Bristol Myers Squibb., Rossi J; CERo Therapeutics., Sharon E; National Cancer Institute., Theoret M; Food and Drug Administration., Vegni F; Bristol Myers Squibb., Yu T; Amgen., Allen J; Friends of Cancer Research.

Source: Cytotherapy [Cytotherapy] 2022 Jul; Vol. 24 (7), pp. 742-749. Date of Electronic Publication: 2022 Feb 23.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 100895309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-2566 (Electronic) Linking ISSN: 14653249 NLM ISO Abbreviation: Cytotherapy Subsets: MEDLINE

MeSH Terms: Cytokine Release Syndrome*/etiology , Immunotherapy*/adverse effects , Neoplasms*/therapy, Antibodies, Bispecific ; Clinical Trials as Topic ; Humans ; Immunotherapy, Adoptive/adverse effects

Authors: Okoye E; Stockport NHS Foundation Trust, Saikali SW; Clemenceau Medical Center

Source: 2022 Jan.

Source: In: StatPearls

Publication Type: Review

Journal Info: Publisher: StatPearls Publishing Cited Medium: Internet

Authors: Lin M; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Narkcham S; Department of Pathology, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand., Jones A; BioReference Laboratories, Houston, Texas., Armylagos D; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., DiPietro B; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Okafor O; BioReference Laboratories, Houston, Texas., Tracey P; BioReference Laboratories, Houston, Texas., Vercher T; BioReference Laboratories, Houston, Texas., Vasquez S; BioReference Laboratories, Houston, Texas., Haley S; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Crumley S; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Gorman B; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Jacobi E; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Amrikachi M; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Coffey D; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Mody D; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas., Okoye E; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas. Electronic address: EIOkoye@houstonmethodist.org.

Source: Journal of the American Society of Cytopathology [J Am Soc Cytopathol] 2022 Jan-Feb; Vol. 11 (1), pp. 3-12. Date of Electronic Publication: 2021 Aug 09.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101613234 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2945 (Print) Linking ISSN: 22132953 NLM ISO Abbreviation: J Am Soc Cytopathol Subsets: MEDLINE

MeSH Terms: Adenocarcinoma/*diagnosis , Adenocarcinoma in Situ/*diagnosis , Papanicolaou Test/*statistics & numerical data , Uterine Cervical Neoplasms/*diagnosis, Adenocarcinoma/pathology ; Adenocarcinoma in Situ/pathology ; Adult ; Biopsy ; Cervix Uteri/pathology ; False Negative Reactions ; Female ; Humans ; Observer Variation ; Papanicolaou Test/standards ; Retrospective Studies ; Uterine Cervical Neoplasms/pathology

Authors: Rajaretnam N; Imperial College London / Derriford Hosp, Okoye E; Stockport NHS Foundation Trust, Burns B; East Tennessee State University (ETSU)

Source: 2022 Jan.

Source: In: StatPearls

Publication Type: Study Guide

Journal Info: Publisher: StatPearls Publishing Cited Medium: Internet

Authors: Rajaretnam N; Imperial College London / Derriford Hosp, Okoye E; Stockport NHS Foundation Trust, Burns B; East Tennessee State University (ETSU)

Source: 2022 Jan.

Source: In: StatPearls

Publication Type: Study Guide

Journal Info: Publisher: StatPearls Publishing Cited Medium: Internet

Authors: Kowalski A; Mclaren Macomb, Okoye E; Stockport NHS Foundation Trust

Source: 2022 Jan.

Source: In: StatPearls

Publication Type: Study Guide

Journal Info: Publisher: StatPearls Publishing Cited Medium: Internet

Authors: Rischin D; Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia danny.rischin@petermac.org., Khushalani NI; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Schmults CD; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Guminski A; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia., Chang ALS; Department of Dermatology, Stanford University School of Medicine, Redwood City, California, USA., Lewis KD; Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA., Lim AM; Department of Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia., Hernandez-Aya L; Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri, USA., Hughes BGM; Department of Cancer Care Services, Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, Queensland, Australia., Schadendorf D; Department of Dermatology, University Hospital Essen; German Cancer Consortium, Essen, Germany., Hauschild A; Department of Dermatology, Schleswig-Holstein University Hospital, Kiel, Germany., Thai AA; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Stankevich E; Regeneron Pharmaceuticals, Tarrytown, New York, USA., Booth J; Regeneron Pharmaceuticals, Tarrytown, New York, USA., Yoo SY; Regeneron Pharmaceuticals, Tarrytown, New York, USA., Li S; Regeneron Pharmaceuticals, Tarrytown, New York, USA., Chen Z; Regeneron Pharmaceuticals, Tarrytown, New York, USA., Okoye E; Regeneron Pharmaceuticals, Tarrytown, New York, USA., Chen CI; Regeneron Pharmaceuticals, Tarrytown, New York, USA., Mastey V; Regeneron Pharmaceuticals, Tarrytown, New York, USA., Sasane M; Sanofi, Bridgewater Township, New Jersey, USA., Lowy I; Regeneron Pharmaceuticals, Tarrytown, New York, USA., Fury MG; Regeneron Pharmaceuticals, Tarrytown, New York, USA., Migden MR; Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Aug; Vol. 9 (8).

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized/*therapeutic use , Carcinoma, Squamous Cell/*drug therapy , Skin Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/pharmacology ; Carcinoma, Squamous Cell/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Quality of Life ; Skin Neoplasms/pathology ; Treatment Outcome

Authors: Stratigos AJ; First Department of Dermatology-Venereology, Andreas Syggros Hospital-National and Kapodistrian University of Athens, Athens, Greece. Electronic address: alstrat@med.uoa.gr., Sekulic A; Arizona Mayo Clinic, Phoenix, AZ, USA., Peris K; Catholic University of the Sacred Heart and Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy., Bechter O; Department of General Medical Oncology, University Hospitals, Leuven, Belgium., Prey S; Department of Dermatology, University Medical Center, Bordeaux, France., Kaatz M; SRH Wald-Klinikum Gera, Gera, Germany., Lewis KD; University of Colorado Cancer Center, Aurora, CO, USA., Basset-Seguin N; Hopital Saint-Louis, Paris, France., Chang ALS; Department of Dermatology, Stanford University School of Medicine, Stanford, CA, USA., Dalle S; Department of Dermatology, HCL Cancer Institute, Lyon Cancer Research Center, Lyon, France., Orland AF; Hospital Universitario Virgen Macarena, Seville, Spain., Licitra L; Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy., Robert C; Dermatology Unit, Gustave Roussy Cancer Center, Villejuif, France; Paris-Saclay University, Villejuif, France., Ulrich C; Charite-Universitiitsmedizin Berlin, Berlin, Germany., Hauschild A; Department of Dermatology, University of Kiel, Kiel, Germany., Migden MR; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Dummer R; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Li S; Regeneron Pharmaceuticals, Basking Ridge, NJ, USA., Yoo SY; Regeneron Pharmaceuticals, Basking Ridge, NJ, USA., Mohan K; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Coates E; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Jankovic V; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Fiaschi N; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Okoye E; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Bassukas ID; University of Ioánnina, Ioánnina, Greece., Loquai C; Department of Dermatology, University Medical Center Mainz, Mainz, Germany., De Giorgi V; Department of Dermatology, University of Florence, Florence, Italy., Eroglu Z; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., Gutzmer R; Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany., Ulrich J; Skin Cancer Center, Department of Dermatology, Harz Clinics, Quedlinburg, Germany., Puig S; Hospital Clínic de Barcelona, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Universitat de Barcelona, and Centro de Investigación Biomèdica en Red de Enfermedadees Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain., Seebach F; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Thurston G; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Weinreich DM; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Yancopoulos GD; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Lowy I; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Bowler T; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Fury MG; Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Source: The Lancet. Oncology [Lancet Oncol] 2021 Jun; Vol. 22 (6), pp. 848-857. Date of Electronic Publication: 2021 May 14.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized/*administration & dosage , Carcinoma, Basal Cell/*drug therapy , Neoplasm Recurrence, Local/*drug therapy , Programmed Cell Death 1 Receptor/*antagonists & inhibitors , Skin Neoplasms/*drug therapy, Adult ; Aged ; Anilides/administration & dosage ; Anilides/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Basal Cell/genetics ; Carcinoma, Basal Cell/pathology ; Drug Resistance, Neoplasm/genetics ; Female ; Hedgehog Proteins/antagonists & inhibitors ; Hedgehog Proteins/genetics ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Immune Checkpoint Inhibitors/adverse effects ; Male ; Middle Aged ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Programmed Cell Death 1 Receptor/genetics ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Skin Neoplasms/genetics ; Skin Neoplasms/pathology

Authors: Kowalski A; Mclaren Macomb, Okoye E; Stockport NHS Foundation Trust

Source: 2021 Jan.

Source: In: StatPearls

Publication Type: Review

Journal Info: Publisher: StatPearls Publishing Cited Medium: Internet

Authors: Okoye E; Stockport NHS Foundation Trust, Saikali SW; Clemenceau Medical Center

Source: 2021 Jan.

Source: In: StatPearls

Publication Type: Review

Journal Info: Publisher: StatPearls Publishing Cited Medium: Internet

Authors: Rischin D; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia danny.rischin@petermac.org., Migden MR; Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lim AM; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Schmults CD; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Khushalani NI; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA., Hughes BGM; Royal Brisbane and Women's Hospital and the University of Queensland, Brisbane, Queensland, Australia., Schadendorf D; University Hospital Essen, Essen and German Cancer Consortium, Essen, Germany., Dunn LA; Department of Medicine, Head and Neck Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Hernandez-Aya L; Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA., Chang ALS; Department of Dermatology, Stanford University School of Medicine, Redwood City, California, USA., Modi B; Division of Dermatology, City of Hope, Duarte, California, USA., Hauschild A; Department of Dermatology, University Hospital (UKSH), Kiel, Germany., Ulrich C; Skin Cancer Centre, Charité Universitätsmedizin Berlin, Berlin, Germany., Eigentler T; Department of Dermatology, Center for Dermatooncology, University Medical Center Tübingen, Tübingen, Germany., Stein B; Adelaide Cancer Centre, Adelaide, South Australia, Australia., Pavlick AC; Department of Medical Oncology, New York University Langone Medical Center, New York, New York, USA., Geiger JL; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA., Gutzmer R; Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany., Alam M; Department of Dermatology, Northwestern University, Chicago, Illinois, USA., Okoye E; Regeneron Pharmaceuticals, Inc, London, UK., Mathias M; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Jankovic V; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Stankevich E; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Booth J; Regeneron Pharmaceuticals, Inc, Basking Ridge, New Jersey, USA., Li S; Regeneron Pharmaceuticals, Inc, Basking Ridge, New Jersey, USA., Lowy I; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Fury MG; Regeneron Pharmaceuticals, Inc, Tarrytown, New York, USA., Guminski A; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Jun; Vol. 8 (1).

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

MeSH Terms: Antibodies, Monoclonal, Humanized/*administration & dosage , Carcinoma, Squamous Cell/*drug therapy , Immune Checkpoint Inhibitors/*administration & dosage , Skin Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Body Weight ; Carcinoma, Squamous Cell/immunology ; Carcinoma, Squamous Cell/mortality ; Carcinoma, Squamous Cell/secondary ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Dosage Calculations ; Female ; Follow-Up Studies ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Infusions, Intravenous ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Progression-Free Survival ; Skin Neoplasms/immunology ; Skin Neoplasms/mortality ; Skin Neoplasms/pathology

Authors: Sharpe M; Department of Vascular and Endovascular Surgery, The Royal Oldham Hospital, Pennine Acute Hospitals NHS Trust, Manchester, UK., Okoye E; Department of Vascular and Endovascular Surgery, The Royal Oldham Hospital, Pennine Acute Hospitals NHS Trust, Manchester, UK., Antoniou GA; Department of Vascular and Endovascular Surgery, The Royal Oldham Hospital, Pennine Acute Hospitals NHS Trust, Manchester, UK - georgios.antoniou@pat.nhs.uk.; Division of Cardiovascular Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.

Source: International angiology : a journal of the International Union of Angiology [Int Angiol] 2020 Feb; Vol. 39 (1), pp. 50-59. Date of Electronic Publication: 2019 Nov 25.

Publication Type: Journal Article; Meta-Analysis; Review

Journal Info: Publisher: Minerva Medica Country of Publication: Italy NLM ID: 8402693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1827-1839 (Electronic) Linking ISSN: 03929590 NLM ISO Abbreviation: Int Angiol Subsets: MEDLINE

MeSH Terms: Amputation, Surgical*, Endovascular Procedures/*adverse effects , Endovascular Procedures/*mortality , Muscle, Skeletal/*pathology , Peripheral Arterial Disease/*surgery, Disease-Free Survival ; Humans ; Limb Salvage ; Lower Extremity/blood supply ; Organ Size ; Peripheral Arterial Disease/mortality ; Prognosis ; Risk Factors ; Time Factors ; Treatment Outcome

Authors: Akosile C; Nnamdi Azikiwe University, Medical Rehabilitation., Nworah C; Nnamdi Azikiwe University, Medical Rehabilitation., Okoye E; Nnamdi Azikiwe University, Medical Rehabilitation., Adegoke B; University of Ibadan, Department of Physiotherapy., Umunnah J; Nnamdi Azikiwe University, Medical Rehabilitation., Fabunmi A; University of Ibadan, Department of Physiotherapy.

Source: African health sciences [Afr Health Sci] 2016 Sep; Vol. 16 (3), pp. 772-780.

Publication Type: Journal Article

Journal Info: Publisher: Faculty of Medicine, Makerere University Country of Publication: Uganda NLM ID: 101149451 Publication Model: Print Cited Medium: Internet ISSN: 1729-0503 (Electronic) Linking ISSN: 16806905 NLM ISO Abbreviation: Afr Health Sci Subsets: MEDLINE